Compare Mesoblast Limited (MESO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Stanley Black & Decker, Inc. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 7.7× Mesoblast Limited's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| MESO | SWK | |
|---|---|---|
Market Cap | $1.75B | $13.47B |
Volume | 239,027 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $20.96 | $104.00 |
52-Week Low | $13.19 | $62.12 |
Typical Hold Time | 15 Days | 62 Days |
Enterprise Value | $1.83B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Stanley Black & Decker (SWK) trades at $89.17, showing modest daily gains of 0.97%. The stock exhibits bearish technical signals with neutral oscillators, while fundamentals show improving profitability with three consecutive quarterly earnings beats. Recent product launches and margin improvement initiatives support growth prospects, though cash flow trends remain mixed. The company maintains Dividend King status with over 200 years of dividend payments.
SWK presents a balanced opportunity with improving earnings momentum and attractive valuation metrics, though technical weakness and margin pressures warrant caution. Analyst consensus leans neutral with a $93 price target suggesting limited upside. Key risks include execution challenges in margin improvement and competitive pressures in the tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
